SORIATANE
ACITRETIN
Approval overview SORIATANE is listed in Drugs@FDA under application 019821 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient ACITRETIN Form and strength CAPSULE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor STIEFEL LABS INC Submission history Latest submission status date: 2023-02-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview SORIATANE is listed in Drugs@FDA under application 019821 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ACITRETIN Form and strength CAPSULE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor STIEFEL LABS INC Submission history Latest submission status date: 2023-02-22 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.